---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-060352"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T11:45:43.588420+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oruka Therapeutics appoints Laura Sandler as COO, effective July 1, 2025

## Summary
- Base salary of $460,000 per year; eligible for annual bonus targeted at 40% of base.
- Granted option to purchase 25,000 shares of common stock; vests 25% on first anniversary, then monthly over 36 months.
- Severance: 12 months base salary if terminated without cause or for good reason outside change-in-control period.
- Within change-in-control period: severance of 1x base salary plus target bonus, plus full equity acceleration.
- Sandler previously served as SVP of Operations at Oruka since March 2024.

## SEC filing metadata
- accession: 0001213900-25-060352
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390025060352/0001213900-25-060352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390025060352/ea0247670-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-060352
- JSON: https://secwatch.observer/filing/0001213900-25-060352.json
- Plain text: https://secwatch.observer/filing/0001213900-25-060352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.